GSK's pre-filled shingles vaccine accepted for review by EMA.
GSK has announced that a pre-filled syringe version of its Shingrix shingles vaccine has been accepted for review by the European Medicines Agency.
GSK
27 January 2025 07:19:31
Source: Sharecast
Shringrix, which has already been administered to over 25m people across the continent since 2018, currently comes as a separate powder and liquid adjuvant, which need to be reconstituted in separate vials prior to administration.
A pre-filled solution, if approved, would offer a more convenient option for physicians, pharmacists and other healthcare professionals, GSK said.
The pre-filled version, which was approved by the US Food and Drug Administration earlier this month, is also being targeted at other markets, GSK said.
It is estimated that one in three adult will develop shingles in their lifetime, and 30% can experience post-herpetic neuralgia or PHN, a long-lasting nerve pain that can last weeks, month or in some cases years.
Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.
